Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Steven Lo | President, CEO & Director | 751.4k | -- | 1967 |
| Dr. Sean N. Tucker Ph.D. | Senior VP & Chief Scientific Officer | 622.44k | -- | 1968 |
| Dr. James F. Cummings M.D. | Chief Medical Officer | 679.94k | -- | 1967 |
| Mr. Phillip Eric Lee | CFO, Principal Financial Officer & Principal Accounting Officer | -- | -- | 1988 |
| Dr. Raymond D. Stapleton Jr., Ph.D. | Chief Technology Officer | -- | -- | 1972 |
| Mr. Edward B. Berg | Senior VP & General Counsel | -- | -- | 1965 |
| Ms. Laurie Hastings | Senior Vice President of Human Resources | -- | -- | -- |
| Ms. Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management | -- | -- | -- |
| Dr. Rajesh Kapoor Ph.D. | Senior Vice President of Quality | -- | -- | -- |
Vaxart, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 105
Description
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
May 12, 2025 at 8:00 PM UTC - May 16, 2025 at 8:00 PM UTC
Vaxart, Inc. Earnings Date